<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:38089257;
mso-list-type:hybrid;
mso-list-template-ids:831029900 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1
{mso-list-id:1195509159;
mso-list-template-ids:340535252;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://gastro.org/research-and-awards/apply-for-awards/award/aga-pilot-research-award-in-health-disparities/">American Gastroenterological Association: Digestive Disease Health Disparities Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Grants of up to $30,000 will be awarded to recipients at any career stage establishing new research projects in digestive disease health and healthcare disparities. Projects must be related to understanding
the causes of such disparities or testing interventions intended to eliminate them. They may focus on the pathophysiology, epidemiology, prevention, diagnosis, patient access to or quality of care, treatment, or patient outcomes of digestive diseases or disorders
associated with a health difference closely linked with economic, social, or environmental disadvantages. Applicants performing any type of research (basic, translational, clinical) relevant to digestive disorders are eligible to apply.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through the program, there are numerous awards available: <o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">AGA Pilot Research Award in Health Disparities</span></b><span style="font-family:Palatino">: Open to investigations of disparities associated
with any digestive disease or disorder. A total of two awards are available.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">AGA-Amgen Pilot Research Award in Health Disparities</span></b><span style="font-family:Palatino">: Open to investigations of disparities associated
with any digestive disease or disorder. One award is available.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">AGA-Bristol Myers Squibb Pilot Research Award in Inflammatory Bowel Disease Health Disparities</span></b><span style="font-family:Palatino">:
Open to investigations of disparities in inflammatory bowel disease. One award is available.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">AGA-Merck Pilot Research Award in Colorectal Cancer Health Disparities</span></b><span style="font-family:Palatino">: Open to investigations of
disparities in colorectal cancer. One award is available.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">AGA-Pfizer Pilot Research Award in Inflammatory Bowel Disease Health Disparities</span></b><span style="font-family:Palatino">: Open to investigations
of disparities in inflammatory bowel disease. One award is available.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due August 26, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: August 18.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://gastro.org/research-and-awards/apply-for-awards/award/aga-medtronic-pilot-research-award-in-artificial-intelligence/">American Gastroenterological Association-Medtronic Pilot Research
Award in Artificial Intelligence</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This award provides $30,000 for one year to independent investigators at any career stage to support research on artificial intelligence for applications in gastroenterology, hepatology, pancreatology
and/or endoscopy. The objective of this AGA Research Foundation Pilot Research Award is to provide funds to early career investigators to help establish their research careers
<b>or</b> to support projects that represent new research directions for established investigators. Projects must be clinically relevant and focus on the development, implementation, or evaluation of artificial intelligence (AI) for applications in gastroenterology,
hepatology, pancreatology and/or endoscopy. Proposals addressing health economics or quality improvement will also be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due August 26, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: August 18.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.concernfoundation.org/apply-for-a-grant" target="_blank">Concern Foundation: Conquer Cancer Now Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Concern Foundation helps to bridge the gap that currently exists in the scientific research community by supporting promising early career scientists and providing critically-needed “seed” money for
innovative research projects. To advance this mission, the foundation is inviting Letters of Intent for its Conquer Cancer Now Award program. Through the program, grants of $60,000 a year for up to two years will be awarded to researchers in support of innovative
research in the areas of cancer genetics, cancer biology, or cancer immunology. The foundation does not fund clinical trials, cancer epidemiology, or behavioral studies. To be eligible, applicants must be an independent investigator at the start of his/her
scientific career (i.e., junior faculty) and at the level of assistant professor (or equivalent, with explanation). PIs must have been in their current position for at least one year at the time of submission of the LOI.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due September 8, 2021. Note: Pre-eligibility questionnaire closes September 6.
<span style="color:red">Med-RA deadline to receive draft documents: August 25 (due to Labor Day holiday).</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://cdmrp.army.mil/funding/crrp" target="_blank">Combat Readiness Medical Research Program</a><br>
<b>Rapid Development and Translational Research Award</b><br>
Pre-application (preproposal): August 31, 2021. Invited full application: December 1, 2021.
<b><span style="color:red">Med-RA deadline to receive draft documents for preproposal due date: August 18.</span></b></span><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Focus areas include sleep disorders and would care solutions.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-294.html">Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental
insights into cancer inflammation <i>in vivo</i>. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on
<i>in vitro</i> and <i>ex vivo</i> methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical
investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of
<i>in vivo</i> inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong
cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-288.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-289.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings
provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate,
via the same electrodes, allows for direct causal tests by modulating network dynamics. These FOAs aim to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited
to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of these FOAs, though development of novel tools/methods to enable relevant mental health studies is encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">NCI Research Specialist Awards: Core-based Scientist and Laboratory-based Scientist (R50 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino">These Funding Opportunity Announcements (FOAs) invite grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-286.html" target="_blank">R50 Core-based Scientist</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an
existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining
the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/par-21-285.html" target="_blank">R50 Laboratory-based Scientist</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an
existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical
research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due November 1, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: October 19.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:red"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-236.html">BRAIN Initiative Cell Atlas Network (BICAN): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain
Cell Atlases (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay
cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, and mouse, in coordination and collaboration with other BRAIN Initiative Cell Atlas Network (BICAN) projects. In particular, the Specialized Collaboratories
are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community,
providing a molecular and anatomical foundational framework for the study of brain function and disorders.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due November 9, 2021.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: October 27.</span></b><b><span style="font-family:Palatino;color:black"><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:red"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-018.html">Pilot and Feasibility Studies to Improve Technology Adoption and Reduce Health Disparities in Type 1 Diabetes Mellitus
(R01 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement (FOA) is to support pilot and feasibility trials of interventions designed to improve technology adoption in individuals from underrepresented
backgrounds with type 1 diabetes mellitus (T1D). Through successful execution, these pilot and feasibility trials should provide feasibility data for larger, pragmatic trials with the overarching goal of reducing health disparity in T1D through improving technology
usage in individuals from minority racial and ethnic backgrounds.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due March 3, 2022.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: February 21.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b>.</b></span><o:p></o:p></p>
</div>
</body>
</html>